PCRX Analyst Ratings
Pacira BioSciences, Inc. (PCRX) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, with a market capitalization near $1.43B, listed on NASDAQ, employing roughly 827 people, carrying a beta of 0.25 to the broader market. Operating within the United States, Pacira BioSciences, Inc. Led by Frank D. Lee, public since 2011-02-03.
Analyst Ratings
In the October 2026 monthly count, 14 analysts rated PCRX: 1 Strong Buy, 4 Buy, 8 Hold, 0 Sell and 1 Strong Sell.
Twelve months earlier, in October 2025: 6 analysts, 1 Strong Buy, 2 Buy, 2 Hold, 0 Sell and 1 Strong Sell.
Price Targets
- Average Target
- $31.67
- Median Target
- $32.00
- High
- $36.50
- Low
- $25.00
- Targets Published, Last 12 Months
- 9
Recent Price Targets
The 5 most recent of 9 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Oct 9, 2026 | H.C. Wainwright | Not named | $36.50 | $36.39 |
| Oct 9, 2026 | Truist Financial | Not named | $36.50 | $36.39 |
| Oct 7, 2026 | Truist Financial | Not named | $31.00 | $25.41 |
| Sep 23, 2026 | Oppenheimer | Not named | $32.00 | $24.70 |
| Sep 9, 2026 | Leerink Partners | Not named | $28.00 | $25.87 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Oct 9, 2026 | Truist Securities | downgrade | Buy | Hold |
| Oct 9, 2026 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| Oct 8, 2026 | Jefferies | downgrade | Buy | Hold |
| Oct 8, 2026 | Needham | downgrade | Buy | Hold |
Quantitative Rating
PCRX carries a model grade of B (overall score 3 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read PCRX Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked PCRX analyst ratings questions
- What is the PCRX consensus price target?
- As of the latest aggregator update, Pacira BioSciences, Inc. (PCRX) carries a consensus 12-month price target of $31.67. Target ranges run from a low of $25.00 to a high of $36.50. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on PCRX?
- In the October 2026 monthly count, 14 analysts rated PCRX, and the distribution is concentrated at Hold: 1 Strong Buy, 4 Buy, 8 Hold, 0 Sell and 1 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has PCRX seen?
- The five most recent ratings actions on PCRX appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect PCRX options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.